Cortexyme and Lilly remind investors that Alzheimer’s failures happen
While Lilly has thrown in the tau towel with zagotenemab, Cortexyme still sees reasons to press on with atuzaginstat.
AC Immune claims a tau win in Alzheimer’s
But mixed data and a previous failure provide reasons to be cautious.
Biogen deals the tau pipeline another blow
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Semorinemab failure tempers tau hopes
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
Sola setback spawns new Alzheimer’s work for Lilly
Despite widespread failures biopharma presses on in Alzheimer's, with approaches including BACE and Tau inhibition.